Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT00005797
First received: June 2, 2000
Last updated: October 24, 2012
Last verified: October 2012

June 2, 2000
October 24, 2012
March 1993
July 2007   (final data collection date for primary outcome measure)
Relapse-free survival [ Time Frame: 5 years post transplant ] [ Designated as safety issue: No ]
Relapse free survival 5 post transplant deteremiend by the Kaplan-Meier product-limit method.
Not Provided
Complete list of historical versions of study NCT00005797 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with hematologic cancers.

OBJECTIVES:

  • Determine the progression free survival (PFS) and overall survival (OS) of patients with low risk myeloid disorders or older allogeneic recipients who are treated with high dose busulfan and cyclophosphamide and allogeneic bone marrow transplantation (BMT).
  • Determine the PFS and OS in patients with lymphoid and high risk myeloid disorders who are treated with etoposide, total body irradiation, and allogeneic BMT.
  • Evaluate the toxicities of these 2 regimens when combined with cyclosporine and methotrexate as graft versus host disease prophylaxis in these patients.
  • Evaluate the PFS and OS of allogeneic BMT in patients with multiple myeloma and chronic lymphocytic leukemia.

OUTLINE:

  • Regimen A: Patients with chronic myelogenous leukemia (CP1, AP/CP2) and other myeloproliferative disorders, myelodysplastic disorders, acute myelogenous leukemia (CR1), or multiple myeloma (not eligible to receive total body irradiation due to prior radiation) are treated with high dose busulfan and cyclophosphamide followed by allogeneic bone marrow transplantation (BMT). Patients receive oral busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 1 hour on days -3 and -2. Allogeneic bone marrow is infused on day 0.
  • Regimen B: Patients with acute myelogenous leukemia (at least CR2, relapsed), acute lymphoid leukemia (ALL), any acute leukemia with CNS involvement, multiple myeloma, or chronic lymphocytic leukemia are treated with total body irradiation and etoposide followed by allogeneic BMT. Patients receive total body irradiation (TBI) on days -7 to -4 for a total of 11 fractions and etoposide IV over 4 hours on day -3. Male patients with ALL receive a testicular boost in 2 fractions on 2 successive days during TBI. Allogeneic bone marrow is infused on day 0.

Patients in both regimens receive cyclosporine and methotrexate as graft versus host disease prophylaxis.

Patients are followed weekly for 3 months and then monthly for 1 year.

PROJECTED ACCRUAL: At least 50 patients with low risk myeloid disease, 50 patients with lymphoid malignancies, and 60 patients with high risk myeloid disease will be accrued for this study.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Multiple Myeloma and Malignant Plasma Cell Neoplasms
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Drug: busulfan
    administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
    Other Name: Busulfex®
  • Drug: Cyclophosphamide
    administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
  • Drug: VP-16
    administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
    Other Name: Etoposide (VP-16; Vepesid(R) brand only)
  • Radiation: Fractionated Total Body Irradiation (FTBI)
    FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
  • BuCy2
    Busulfan & Cyclophosphamide
    Interventions:
    • Drug: busulfan
    • Drug: Cyclophosphamide
  • VP16/TBI
    Fractionated Total Body Irradiation + VP-16
    Interventions:
    • Drug: VP-16
    • Radiation: Fractionated Total Body Irradiation (FTBI)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
125
July 2007
July 2007   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of:

    • Acute myelogenous leukemia

      • Complete remission (CR) 1 - ALL except good cytogenetics defined as [(inv16, t(8,21), t(15,17)]
      • CR2
      • Induction failures
      • Relapsed OR
    • Acute lymphocytic leukemia (ALL)

      • CR1 - high risk defined as overt CNS involvement, 1 or more risk factors (age 30 and over, WBC at least 20,000/mm^3, at least 4 weeks to CR1, myeloid phenotype)
      • CR2
      • Induction failures
      • Relapsed OR
    • Chronic myelogenous leukemia

      • Chronic phase (CP) 1
      • Accelerated phase (AP)/CP2 OR
    • Chronic lymphocytic leukemia

      • At diagnosis - RAI stage III/IV or Binet C

        • Must undergo 1 induction regimen
      • Relapsed - any stage

        • Must have received no more than 3 regimens for diagnosis OR
    • Multiple myeloma

      • At diagnosis - stage II/III (primary refractory or sensitive)
      • Relapsed no more than 2 times - sensitive disease
      • Plasma cell leukemia OR
    • Myelodysplasia

      • All subtypes eligible OR
    • Myeloproliferative disorders

      • Poor response to medical therapy OR
      • Cytogenetic abnormalities
  • Must have a related donor who is genotypic 6 out of 6 HLA A, B, and DR match

    • Molecular DR matching required

PATIENT CHARACTERISTICS:

Age:

  • 15 to 55

Performance status:

  • Karnofsky 80-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • Bilirubin no greater than 2.0 mg/dL
  • SGOT/SGPT no greater than 3 times upper limit of normal
  • PT/PTT normal

Renal:

  • Creatinine no greater than 2.0 mg/dL
  • Creatinine clearance at least 60 mL/min

Cardiovascular:

  • LVEF at least 45% by MUGA scan or echocardiography
  • No myocardial infarction within the past 6 months
  • No arrhythmias controlled by therapy

Pulmonary:

  • FEV_1 at least 50% predicted
  • DLCO at least 50% predicted

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • No diabetes mellitus or thyroid disease that is not medically controlled
  • No psychosocial disorder that would preclude study compliance
  • No active serious infections
  • HIV negative
  • Donor must be HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified
Both
15 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00005797
MCC-11281, MCC-IRB-4188, NCI-G00-1759
No
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Study Chair: Teresa Field, MD, PhD H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP